Key Highlights
- Smith & Nephew, the London-listed medical-technology group behind artificial hips and knees, sports-medicine tools and advanced wound-care dressings.
- Its second-quarter and half-year results on 4 August 2026 delivered a mixed verdict — steady profit progress undercut by softer Revenue and, most pointedly, the departure of its chief financial officer.
- Revenue rose to $3,097m, up 4.6% reported but only 2.3% underlying, while second-quarter underlying growth slowed to 1.6%.
- Crucially, trading profit climbed 8.1% to $566m and the trading Margin expanded 60 basis points to 18.3% — evidence that chief executive Deepak Nath's efficiency and operational-improvement programme is bearing fruit.
Smith & Nephew, the London-listed medical-technology group behind artificial hips and knees, sports-medicine tools and advanced wound-care dressings, has spent several years trying to convince investors that its long-promised turnaround is real. Its second-quarter and half-year results on 4 August 2026 delivered a mixed verdict — steady profit progress undercut by softer revenue and, most pointedly, the departure of its chief financial officer. For a company whose recovery hinges on execution and credibility, the timing of a senior boardroom change sharpened the Leadership test investors were already applying, and revived the question of whether the improvement is being driven by self-help or by a favourable market.
The results
The first-half numbers showed a Business improving on profitability even as the Top Line disappointed. Revenue rose to $3,097m, up 4.6% reported but only 2.3% underlying, while second-quarter underlying growth slowed to 1.6%. Crucially, trading profit climbed 8.1% to $566m and the trading margin expanded 60 basis points to 18.3% — evidence that chief executive Deepak Nath's efficiency and operational-improvement programme is bearing fruit. Adjusted Earnings Per Share rose 11% and the Interim Dividend was lifted 4%. But management cut full-year underlying revenue guidance from about 6% to around 4%, an acknowledgement that Demand in parts of the portfolio has proved weaker than planned.
A tale of three divisions
The divisional picture explained the caution. Sports Medicine & ENT was the standout, with second-quarter revenue up 10% led by the REGENETEN and Q-FIX shoulder-repair franchises and a margin nudging 24.7%. Orthopaedics, the historic weak spot, was broadly flat as US knee-implant sales stayed under pressure despite traction for the LEGION robotics-enabled system. Advanced Wound Management dipped slightly, hit by US reimbursement changes for skin substitutes. The mix underscores both the group's strengths and the stubbornness of the segments that have long dragged on returns, and explains why the market remains reluctant to award Smith & Nephew the rating enjoyed by faster-growing MedTech peers.
The leadership question
The CFO's exit lands at a delicate moment. Nath has staked his tenure on a multi-point plan to lift margins toward the high-teens and beyond, and continuity in the finance seat matters when investors are weighing whether the improvement is structural or cyclical. A smooth succession and a clear message on Capital allocation will be needed to reassure a Shareholder base that has periodically attracted activist interest and pressure to break up the group or reconsider its listing. Management continuity is now part of the Investment case, not just an operational footnote, and the choice of a permanent successor will be read as a signal about the pace and ambition of the turnaround.
Outlook
Financially the group remains solid. Management maintained guidance for roughly 8% trading-profit growth, about $800m of free Cash Flow and a return on invested capital above 10%, and it is midway through a $500m share buyback announced in May 2026, with $216m completed by early August. That combination of margin expansion, cash generation and Buybacks is the core of the bull case — provided revenue growth does not slip further and undermine the Operating Leverage the plan depends on. A buyback also flatters per-share metrics, so investors will look for underlying trading profit and cash flow to keep improving in their own right rather than relying on a shrinking share count. Risks include continued softness in US orthopaedics, reimbursement headwinds in wound care, currency swings and the execution demands of a multi-year restructuring now navigating a leadership change. Orthopaedics competes against larger, better-capitalised rivals in a market where hospital purchasing decisions and surgeon preferences change slowly, so recovering share there is a multi-year task rather than a quick fix. Investors may watch for the permanent CFO appointment, third-quarter revenue trends and any sign that orthopaedics can return to growth. The margin story is intact; the growth story still has to be earned.






Please wait processing your request...